vs
Arcturus Therapeutics Holdings Inc.（ARCT）与Rocky Mountain Chocolate Factory, Inc.（RMCF）财务数据对比。点击上方公司名可切换其他公司
Rocky Mountain Chocolate Factory, Inc.的季度营收约是Arcturus Therapeutics Holdings Inc.的1.0倍（$7.5M vs $7.2M），Rocky Mountain Chocolate Factory, Inc.同比增速更快（-4.4% vs -68.4%），Rocky Mountain Chocolate Factory, Inc.自由现金流更多（$-1.3M vs $-74.5M），过去两年Rocky Mountain Chocolate Factory, Inc.的营收复合增速更高（1.9% vs -56.5%）
Arcturus Therapeutics Holdings Inc.是一家专注于RNA药物研发的美国生物科技企业，核心业务覆盖罕见病与传染病领域药物的研发、开发与商业化。该公司自主研发了专属脂质纳米颗粒递送技术，可用于递送小干扰RNA、信使RNA、基因编辑RNA、DNA、反义寡核苷酸、微小RNA等多种核酸药物。
落基山巧克力厂是美国知名巧克力企业，同时开展国际特许经营业务，集糖果生产与零售运营于一体，总部位于美国科罗拉多州杜兰戈，除美国本土门店外，在巴拿马、菲律宾也设有经营网点。
ARCT vs RMCF — 直观对比
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $7.2M | $7.5M |
| 净利润 | — | $-155.0K |
| 毛利率 | — | 34.0% |
| 营业利润率 | — | 1.1% |
| 净利率 | — | -2.1% |
| 营收同比 | -68.4% | -4.4% |
| 净利润同比 | 3.1% | 81.7% |
| 每股收益（稀释后） | — | $-0.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $7.2M | $7.5M | ||
| Q3 25 | $17.2M | $6.8M | ||
| Q2 25 | $28.3M | $6.4M | ||
| Q1 25 | $29.4M | $8.9M | ||
| Q4 24 | $22.8M | $7.9M | ||
| Q3 24 | $41.7M | $6.4M | ||
| Q2 24 | $49.9M | $6.4M | ||
| Q1 24 | $38.0M | $7.3M |
| Q4 25 | — | $-155.0K | ||
| Q3 25 | $-13.4M | $-662.0K | ||
| Q2 25 | $-9.2M | $-324.0K | ||
| Q1 25 | $-14.1M | $-2.9M | ||
| Q4 24 | $-30.0M | $-847.0K | ||
| Q3 24 | $-6.9M | $-722.0K | ||
| Q2 24 | $-17.2M | $-1.7M | ||
| Q1 24 | $-26.8M | $-1.6M |
| Q4 25 | — | 34.0% | ||
| Q3 25 | — | 23.6% | ||
| Q2 25 | — | 31.1% | ||
| Q1 25 | — | 10.8% | ||
| Q4 24 | — | 23.4% | ||
| Q3 24 | — | 31.8% | ||
| Q2 24 | — | 12.8% | ||
| Q1 24 | — | 24.3% |
| Q4 25 | — | 1.1% | ||
| Q3 25 | -96.3% | -7.0% | ||
| Q2 25 | -41.0% | -2.3% | ||
| Q1 25 | -57.3% | -30.3% | ||
| Q4 24 | -146.7% | -8.9% | ||
| Q3 24 | -25.8% | -14.3% | ||
| Q2 24 | -42.4% | -25.4% | ||
| Q1 24 | -80.0% | -21.7% |
| Q4 25 | — | -2.1% | ||
| Q3 25 | -78.4% | -9.7% | ||
| Q2 25 | -32.4% | -5.1% | ||
| Q1 25 | -47.9% | -32.5% | ||
| Q4 24 | -131.8% | -10.7% | ||
| Q3 24 | -16.6% | -11.3% | ||
| Q2 24 | -34.5% | -25.9% | ||
| Q1 24 | -70.5% | -21.9% |
| Q4 25 | — | $-0.02 | ||
| Q3 25 | $-0.49 | $-0.09 | ||
| Q2 25 | $-0.34 | $-0.04 | ||
| Q1 25 | $-0.52 | $-0.38 | ||
| Q4 24 | $-1.10 | $-0.11 | ||
| Q3 24 | $-0.26 | $-0.11 | ||
| Q2 24 | $-0.64 | $-0.26 | ||
| Q1 24 | $-1.00 | $-0.25 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $230.9M | $641.0K |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $214.0M | $6.0M |
| 总资产 | $271.1M | $20.7M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $230.9M | $641.0K | ||
| Q3 25 | $180.4M | $2.0M | ||
| Q2 25 | $196.5M | $893.0K | ||
| Q1 25 | $216.9M | $720.0K | ||
| Q4 24 | $237.0M | $1.1M | ||
| Q3 24 | $237.2M | $973.0K | ||
| Q2 24 | $260.3M | $637.0K | ||
| Q1 24 | $288.4M | $2.1M |
| Q4 25 | $214.0M | $6.0M | ||
| Q3 25 | $224.6M | $6.1M | ||
| Q2 25 | $231.1M | $6.7M | ||
| Q1 25 | $233.8M | $7.0M | ||
| Q4 24 | $241.0M | $9.8M | ||
| Q3 24 | $261.9M | $10.5M | ||
| Q2 24 | $258.6M | $9.0M | ||
| Q1 24 | $264.0M | $10.6M |
| Q4 25 | $271.1M | $20.7M | ||
| Q3 25 | $282.3M | $22.3M | ||
| Q2 25 | $309.3M | $20.1M | ||
| Q1 25 | $331.8M | $21.2M | ||
| Q4 24 | $344.1M | $21.6M | ||
| Q3 24 | $370.7M | $21.1M | ||
| Q2 24 | $388.6M | $19.0M | ||
| Q1 24 | $418.8M | $20.6M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-74.3M | $-1.2M |
| 自由现金流经营现金流 - 资本支出 | $-74.5M | $-1.3M |
| 自由现金流率自由现金流/营收 | -1035.2% | -16.9% |
| 资本支出强度资本支出/营收 | 3.2% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $-74.3M | $-1.2M | ||
| Q3 25 | $-17.2M | $-488.0K | ||
| Q2 25 | $-5.8M | $350.0K | ||
| Q1 25 | $-35.1M | $1.2M | ||
| Q4 24 | $-284.0K | $-2.1M | ||
| Q3 24 | $-23.8M | $-3.5M | ||
| Q2 24 | $-30.1M | $-2.2M | ||
| Q1 24 | $-5.6M | $129.0K |
| Q4 25 | $-74.5M | $-1.3M | ||
| Q3 25 | $-17.3M | $-544.0K | ||
| Q2 25 | — | $182.0K | ||
| Q1 25 | $-35.3M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-23.8M | $-4.6M | ||
| Q2 24 | $-30.5M | $-2.6M | ||
| Q1 24 | $-5.8M | $-352.3K |
| Q4 25 | -1035.2% | -16.9% | ||
| Q3 25 | -101.1% | -8.0% | ||
| Q2 25 | — | 2.9% | ||
| Q1 25 | -120.1% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -57.2% | -72.6% | ||
| Q2 24 | -61.1% | -40.2% | ||
| Q1 24 | -15.3% | -4.9% |
| Q4 25 | 3.2% | 0.5% | ||
| Q3 25 | 1.1% | 0.8% | ||
| Q2 25 | 0.0% | 2.6% | ||
| Q1 25 | 0.5% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.2% | 17.5% | ||
| Q2 24 | 0.7% | 6.5% | ||
| Q1 24 | 0.6% | 6.6% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ARCT
暂无分部数据
RMCF
| Manufacturing | $5.9M | 78% |
| Transferred At Point In Time | $1.2M | 16% |
| Other | $414.0K | 5% |
